[Translated article] Medication reconciliation in pediatric hemato-oncologic patients: A multicenter study

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Vendrell, Margarita Cuervas-mons
- Fuentes, Dolores Pilar Iturgoyen
- Flaque, Miquel Villaronga
- Poy, Maria Jose Cabanas
- Fernandez-llamazares, Cecilia M.
- Del Vayo, Concha Alvarez
- Fernandez, Carmen Gallego
- Roca, Cristina Martinez
- Gago, Yolanda Hernandez
- Corro, Beatriz Garrido
Grupos
Abstract
Objective: To determine the prevalence of reconciliation errors on admission to hospital in the pediatric onco-hematological population in order to check whether they are similarly susceptible to these reconciliation errors as adults and to describe the characteristics of the patients who suffer them.Methods: A 12-month prospective, multicentre study of medication reconciliation on admission in the pediatric onco-hematological population to assess the incidence of reconciliation errors and to describe the characteristics of the patients.Results: Medication reconciliation was performed in 157 patients. At least a medication discrepancy was detected in 96 patients. Of the discrepancies detected, 52.1% were related to patient's new clinical situation or by the physician, while 48.9% were determined to be reconciliation errors. The most frequent type of reconciliation error was the ``omission of a medication'', followed by ``a different dose, frequency or route of administration''. A total of 77 pharmaceutical interventions were carried out, 94.2% of which were accepted. In the group of patients with a number equal to or greater than 4 drugs in home treatment, there was a 2.1-fold increase in the probability of suffering a reconciliation error.Conclusions: In order to avoid or reduce errors in one of the critical safety points such as transitions of care, there are measures such as medication reconciliation. In the case of complex chronic pediatric patients, such as onco-hematological patients, the number of drugs as part of home treatment is the variable that has been associated with the presence of medication reconciliation errors on admission to hospital, and the omission of some medication was the main cause of these errors.(c) 2023 Sociedad Espanola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Copyright © 2023 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Publicado por Elsevier España, S.L.U. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1130-6343, 0214-753X
- Tipo:
- Article
- Páginas:
- 261-267
- PubMed:
- 37716875
- Factor de Impacto:
- 0,264 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
FARMACIA HOSPITALARIA EDITORIAL GARSI
Documentos
- No hay documentos
Filiaciones
Keywords
- Medication reconciliation; Discrepancy; Medication errors; Patient transfer; Pediatrics; Oncology; Hematology
Proyectos y Estudios Clínicos
MULTICENTER, RANDOMIZED, BLINDED CLINICAL STUDY COMPARING EARLY USE OF TOTAL BODY MODERATE HYPOTHERMIA PLUS TOPIRAMATE OR PLACEBO IN ASPHYXIATED NEWBORN INFANTS EVOLVING TO MODERATE-TO-SEVERE HYPOXIC ISCHEMIC ENCEPHALOPATHY
Investigador Principal: MÁXIMO VENTO TORRES
EC11-244 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012
RED DE SALUD MATERNO INFANTIL Y DEL DESARROLLO
Investigador Principal: MÁXIMO VENTO TORRES
RD12/0026/0012 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
RED DE SALUD MATERNO-INFANTIL Y DEL DESARROLLO.
Investigador Principal: MÁXIMO VENTO TORRES
RD16/0022/0001 . INSTITUTO DE SALUD CARLOS III . 2017
Paracetamol versus ibuprofeno en recién nacidos prematuros con diagnóstico de ductus arterioso persistente hemodinamicamente significativo: ensayo clínico aleatorizado.
Investigador Principal: MARTA AGUAR CARRASCOSA
PI18/01696 . INSTITUTO DE SALUD CARLOS III . 2019
EFECTO DEL ALOPURINOL EN PACIENTES CON ENCEFALOPATÍA HIPÓXICO-ISQUÉMICA TRATADOS CON HIPOTERMIA – ALBINO – ENSAYO CLÍNICO MULTICÉNTRICO, ALEATORIZADO, CIEGO, CONTROLADO CON PLACEBO.
Investigador Principal: MÁXIMO VENTO TORRES
ALBINO . 2018
ESTUDIO SOBRE LA UTILIZACIÓN DE MEDICAMENTOS EN CONDICIONES OFF-LABEL Y UNLICENSED EN UNA UNIDAD DE CUIDADOS INTENSIVOS NEONATALES.
Investigador Principal: PILAR SÁENZ GONZÁLEZ
GIP-MED-2017-01 . 2017
IDENTIFICACIÓN DE FACTORES CLÍNICOS, MOLECULARES Y RADIOLÓGICOS PREDICTORES DE RESPUESTA AL TRATAMIENTO CON BEVACIZUMAB EN PACIENTES CON GLIOMAS DE ALTO GRADO: BEVA-GLIO.
Investigador Principal: ANA ALEJANDRA GARCÍA ROBLES
AGR-BEV-2018-01 . 2018
ENSAYO CLÍNICO FASE I PARA ESTABLECER LA SEGURIDAD DEL USO DE CÉLULAS MESENQUIMALES TRONCALES FETALES ALOGÉNICAS DE CORDÓN UMBILICAL EXPANDIDAS EN PACIENTES PREMATUROS CON DISPLASIA BRONCOPULMONAR.
Investigador Principal: MÁXIMO VENTO TORRES
PULMESCEL-1 . 2019
PARACETAMOL VERSUS IBUPROFENO EN RECIÉN NACIDOS PREMATUROS CON DIAGNÓSTICO DE DUCTUS ARTERIOSO PERSISTENTE HEMODINÁMICAMENTE SIGNIFICATIVO: ENSAYO CLÍNICO ALEATORIZADO.
Investigador Principal: MARTA AGUAR CARRASCOSA
IBUPAR-TRIAL . 2017
DISEÑO Y VALIDACIÓN DE LAS DOSIS DIARIAS DEFINIDAS DE ANTIMICROBIANOS EN POBLACIÓN PEDIÁTRICA.
Investigador Principal: ANA ALEJANDRA GARCÍA ROBLES
GAF-TEI-2015-01 . 2021
Proyecto Identity: Identificación de pacientes por biometría de voz en farmacia externa hospitalaria.
Investigador Principal: JOSÉ LUIS POVEDA ANDRÉS
BIOVOZ-2022-01 . 2023
Cita
Vendrell MC,Fuentes DPI,Flaque MV,Poy MJC,Fernandez CM,Del Vayo CA,Fernandez CG,Roca CM,Gago YH,ROBLES AG,Corro BG. [Translated article] Medication reconciliation in pediatric hemato-oncologic patients: A multicenter study. Farm. Hosp. 2023. 47. (6):p. 261-267.